232 related articles for article (PubMed ID: 37955563)
1. Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence.
Vaidya P; Cohen EEW
Clin Cancer Res; 2024 Apr; 30(7):1232-1239. PubMed ID: 37955563
[TBL] [Abstract][Full Text] [Related]
2. Development of postoperative bronchopleural fistula after neoadjuvant immunochemotherapy in non-small cell lung cancer: case reports and review of the literature.
Zhao R; Guan X; Zhang P; Liu Y; Xu Y; Sun C; Qiu S; Zhu W; Yang Z; Wang X
J Cancer Res Clin Oncol; 2024 Apr; 150(4):175. PubMed ID: 38573518
[TBL] [Abstract][Full Text] [Related]
3. Research advances and new challenges in overcoming triple-negative breast cancer.
Zong Y; Pegram M
Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
Dixon-Douglas J; Loi S
Curr Treat Options Oncol; 2023 Aug; 24(8):1004-1020. PubMed ID: 37222922
[TBL] [Abstract][Full Text] [Related]
5. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM; Tsuboi M; Brunelli A
Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
Varma R; Wright M; Abraham J; Kruse M
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
[TBL] [Abstract][Full Text] [Related]
7. Increasing cure rates of solid tumors by immune checkpoint inhibitors.
Ma W; Xue R; Zhu Z; Farrukh H; Song W; Li T; Zheng L; Pan CX
Exp Hematol Oncol; 2023 Jan; 12(1):10. PubMed ID: 36647169
[TBL] [Abstract][Full Text] [Related]
8. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
9. Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.
Mohamed A; Kruse M; Tran J
Expert Rev Anticancer Ther; 2023; 23(10):1071-1084. PubMed ID: 37747062
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant immunotherapy in resectable non-small cell lung cancer.
Lochrin SE; Forde PM
Clin Adv Hematol Oncol; 2023 Aug; (8):415-423. PubMed ID: 37530615
[TBL] [Abstract][Full Text] [Related]
11. Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC.
Friedlaender A; Naidoo J; Banna GL; Metro G; Forde P; Addeo A
Cancer Treat Rev; 2022 Mar; 104():102350. PubMed ID: 35093800
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418
[TBL] [Abstract][Full Text] [Related]
13. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States.
Zaim R; Redekop K; Uyl-de Groot CA
J Cancer Policy; 2022 Sep; 33():100346. PubMed ID: 35779788
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
[TBL] [Abstract][Full Text] [Related]
16. Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer.
Riano I; Abuali I; Sharma A; Durant J; Dragnev KH
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259381
[TBL] [Abstract][Full Text] [Related]
17. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Steiner M; Tan AR
Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer.
Sanber K; Rosner S; Forde PM; Marrone KA
BioDrugs; 2023 Nov; 37(6):775-791. PubMed ID: 37603233
[TBL] [Abstract][Full Text] [Related]
19. Current studies of immunotherapy in head and neck cancer.
Dogan V; Rieckmann T; Münscher A; Busch CJ
Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?
Giugliano F; Valenza C; Tarantino P; Curigliano G
Expert Opin Investig Drugs; 2022 Aug; 31(8):855-874. PubMed ID: 35762248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]